HeartBeam Inc. (NASDAQ: BEAT) has been recognized as a Global IP and Technology Leader in Portable Cardiac Diagnostics by PatentVest’s “Total Cardiac Intelligence” report, ranking second worldwide in 12-lead ECG innovation among 243 firms analyzed, trailing only GE Healthcare. The recognition underscores the rapid maturation of the company’s proprietary synthesis-ECG system, which captures the heart’s electrical signals in three noncoplanar dimensions and synthesizes them into a 12-lead ECG. This unique approach allows physicians to obtain cardiologist-level ECG data from compact devices that can be used by patients or clinicians far from traditional hospital settings.
The article discussing HeartBeam’s ranking highlights that the company is addressing one of modern medicine’s most persistent challenges: delivering high-quality cardiac monitoring for arrhythmia assessment wherever patients are. HeartBeam is currently cleared for arrhythmia detection, with ischemia monitoring as a future goal. The company’s platform technology is designed to be used in portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians can identify cardiac health trends and acute conditions and direct patients to the appropriate care outside of a medical facility.
HeartBeam holds 13 U.S. and 4 international-issued patents related to technology enablement. The company is creating the first-ever cable-free 12-lead ECG capable of capturing the heart’s electrical signals from three dimensions. This innovation is significant because it enables continuous, remote cardiac monitoring that could reduce the need for hospital visits and improve early detection of cardiac events.
For more information, visit HeartBeam. The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT.
